Author of

• 31515

  +

  P2.14 - Targeted Therapy (ID 183)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31547

    +

    P2.14-27 - Efficacy and Prognostic Factor of Apatinib Plus EGFR-TKI in Treating Advanced Non-Small-Cell Lung Cancer with EGFR-TKI Resistance (ID 1519)

    10:15 - 18:15  |  Presenting Author(s): Guilan Dong
    • Abstract

    Background
    

    Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR-TKIs initially. Apatinib is an oral TKI against VEGFR-2 and is effective as third- or later-line treatment in advanced NSCLC. EGFR and VEGF/VEGFR pathways are interrelated. We conducted this study to investigate the efficacy and safety of apatinib plus EGFR-TKI as second-line treatment in patients with advanced NSCLC.

    Method
    

    From August 2017 to December 2018, 23 patients of advanced NSCLC acquired resistance for EGFR-TKI (gefitinib 250mg qd；erlotinib 150mg qd；icotinib 125 mg, bid ) treated with original targeted drugs plus Apatinib (250 mg, qd, orally). Treatment was continued until disease progression or unacceptable toxic effects.

    Result
    

    In 23 patients, there were 17 patients available for efficacy and safety evaluation. the objective response rate (ORR) was 17.6 % and the disease control rate (DCR) was 82.4 %. The median progression-free survival (PFS) was 8.0 months, patients with and without hypertension was 6.8 months and 4.1 months, respectively. The median overall survival had not reached. The most frequent treatment-related adverse events were hypertension (64.7 %, 11/17), hand-foot syndromes (29.4 %, 5/17) and fatigue (11.8 %, 2/17).

    Conclusion
    

    Apatinib plus EGFR-TKI is efficacious in treating patients with advanced NSCLC after EGFR-TKI treatment failure, with acceptable toxic effects. Hypertension could be an effective prognostic factor for in apatinib-treated NSCLC patients.